Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? / Wiendl, Heinz; Bourdette, Dennis; Ciccarelli, Olga.In: Neurology, Vol. 89, No. 11, 01.09.2017, p. 1098-1100.
Research output: Contribution to journal › Editorial › peer-review
TY - JOUR
T1 - Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
AU - Wiendl, Heinz
AU - Bourdette, Dennis
AU - Ciccarelli, Olga
N1 - Funding Information: H.W.’s work is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS). D.B. receives research funding from the U.S. National MS Society. O.C. receives funding from UK MS Society and Rosetree Trust and her work is supported by NIHR UCLH BRC. Funding Information: Heinz Wiendl: honorarium for acting as a member of scientific advisory boards and as a consultant for Biogen, Evgen, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Genzyme; speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Sanofi-Genzyme, TEVA, and WebMD Global; paid consultant for AbbVie, Actelion, Biogen, IGES, Novartis, Roche, Sanofi-Genzyme, and the Swiss Multiple Sclerosis Society; and research funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster and RE Children’s Foundation, Biogen GmbH, GlaxoSmithKline GmbH, Roche Pharma AG, and Sanofi Genzyme. Dennis Bourdette: research grants from the US National MS Society. O.C. serves as a consultant for Biogen, Teva, Sanofi-Genzyme, Roche Pharma AG, Novartis, and GE Healthcare, and she is an associate editor of Neurology. Go to Neurology.org for full disclosures. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/9/1
Y1 - 2017/9/1
UR - http://www.scopus.com/inward/record.url?scp=85033578773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033578773&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000004381
DO - 10.1212/WNL.0000000000004381
M3 - Editorial
C2 - 28835406
AN - SCOPUS:85033578773
VL - 89
SP - 1098
EP - 1100
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 11